Integrated complex treatment approach of the women diagnosed with cervical pathologies and benign ovarian tumors
Taking into account the urgency of the timely diagnosis and adequate correction of endocervix, the study of the relationship between the state of the mucous membrane of the cervical canal and the pelvic organs concomitant pathology, especially the tumor-shaped ovarian formations, in the perspective of developing a diagnostic and tactical treating algorithm represents a significant practical and scientific interest. The purpose of the study:isto pathogenetically substantiate the complex of mediators in the program of post-destructive therapy of cervical pathology for the female patients with tumor-like ovarian formations. Materials and methods of the research: We have selected 60 patients with cervical pathology and tumor-like lesions of the ovaries. The control group consisted of 20 women without pathology of the cervix. To adequately analyze the treatment results patients were divided into the following groups: the first group (main) - 30 patients who received the proposed treatment program. In order to improve the quality of therapy, it was considered to appropriately use the treatment complex, which combines the methods of hormonal correction, antiproliferative drugs (epihalin), as a destructive therapy - arhonoplazmic coagulation and correction of local immune status (thiotriasolin). The second group (group) - 25 patients, were treated with the help of conventional therapies used for background cervical processes, approved by national guidelines and treating protocols. Results of the study and their discussion:The results of the study have shown that patients with tumor-like ovarian tumors should be classified as a risk group for the development of cervical pathology. Various benign diseases of the cervix were diagnosed in 43.3% of cases, means that every other woman represents with tumor-like ovarian lesions CINI - was diagnosed for 18.3% of women, to some extent, is an evidence of hormonal conditioning of the pathological processes in exo- and endocervics for this patients category. Structure of the disease was due to a deviation in the hormonal balance of the metabolic status. The diagnosed hyperandrogenism oftenelyfollows by revealed leukoplakia (in 21.7% of cases). Patients with hyperprolactinemia were diagnosed with ectopia, combined with cervicitis (in 36.7% of cases). The diagnosed typical hypothyroidism and ovarian tissue luteal phase deficiency was followed by chronic exo- and endocervicitis (in 26.7% of cases). The effectiveness of the cervical pathology treatment for the female patients of the main clinical group with diagnosed functional ovarian tumor-likelesions using the differentiated approach was 93.3%. The total duration of treatment with adequate monitoring of such patients does not exceed three menstrual cycles, the rate of relapse is 3.3%. At the same time the remote monitoring of the main group patients with the comparison group at 12 months observation period after the treatment, revealed a low rate of complications and recurrence (p <0.05). The proposed medical program twice reduced the percentage comparing to the conventional treatment with sustained positive effect. Conclusions: The structure of cervical pathologies for the women diagnosed with tumor-like ovarian processes is significantly different and is related to the nature and the degree of hormonal imbalance. This study demonstrates a high therapeutic efficacy of a complex herbal preparation containing two active ingredients: indole-3-carbinol and epigallocatechin-3-gallate. The receptor-fixing, aetiroscogenic, anti-inflammatory and apoptosis-inducing effects of this complex, affects not only the main pathogenetic links of the functional cysts formation of the ovaries, but also prevents proliferative processes of endo- and exocervix and their recurrence. The efficacy of cervical pathology treatmentfor the women with functional tumor-like ovarian lesions with the help of a differentiated approach and a complex herbal preparation containing two active components: indole-3-carbinol and epigallocatechin-3-galate is nearly 93.3%. The overall duration of treatment with adequate monitoring of such patients does not exceed three menstrual cycles, with a relapse rate of 3.3%.
How to cite this article:
Matviykiv NI. Integrated complex treatment approach of the women diagnosed with cervical pathologies and benign ovarian tumors. Pharma Innovation 2017;6(8):106-108.